To discuss the promise of circulating microRNA mmu-miR-721 as one of new approaches to biomarkers for myocarditis diagnosis
"Most recently, CAP TODAY interviewed Dr. Shirley Li, assistant professor in the Department of Pathology, Ohio State University Wexner Medical Center, regarding new approaches to biomarkers for myocarditis diagnosis. At the AACC annual conference 2021, Dr. Li highlighted in her virtual presentation about the diagnostic value of miRNA in myocarditis. She cited the study from Dr. Pilar Martín, which was recently published in N Engl J Med. This study has evaluated and verified the application of miR-721 in the differential diagnosis between myocarditis and myocardial infarction.
“The inflammation and/or necrosis of cardiac tissues could happen at a very close time or in a certain time order, or mixed, happening at the same time,” Dr. Li explains. “We can see the similar trend of dynamic changes of troponin with the dynamic changes of inflammation biomarkers, but we are not able to confirm that troponin can differentiate myocarditis and myocardial infarction. The finding of novel microRNA”—the human homologue, designated as hsa-miR-Chr8:96—“can make it and fill the gap.” Meanwhile, “Troponin is a relatively more specific cardiac biomarker in the diagnosis of myocarditis, even in the course of COVID-19 vaccination,” said Dr. Li.
Please check more details in the interview on CAP TODAY.
最新一期的CAP 就miRNA 在心肌炎诊断的应用上采访了俄亥俄州立大学的李捷莉教授。李教授于去年AACC年会上主持了 有关心脏标志物的研讨会 并指出了miRNA 对心肌病诊断的潜在价值。 她援引了西班牙血管病专家Martin 博士于近期发表在新英格兰医学杂志的研究工作。该项研究评估并论证了miR-721可以用来鉴别诊断心肌炎和心肌梗塞。